The syndrome of inappropriate secretion of antidiuretic hormone associated with SCT: clinical differences following SCT using cord blood and BM/peripheral blood.
Previously, we reported the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) as an underestimated complication associated with SCT. In the present report, we analyzed detailed data on a larger number of patients with SIADH following SCT and found different SIADH clinical features following cord blood SCT (CBSCT) and BMT/PBSCT. The median onset of SIADH following CBSCT and BMT/PBSCT was 19 and 46 days after SCT, respectively, and the median numbers of WBC at the onset of SIADH were 1.0 and 3.1 x 10(9)/l, respectively. Furthermore, severe symptoms such as seizures, somnolence and rigidity of limbs were observed only in patients with CBSCT (8/15 vs 0/10). These differences were statistically significant (P<0.01). Although the precise basis for SIADH following SCT still remains unknown, the different features of SIADH observed following CBSCT and BMT/PBSCT may provide important clues to the disease mechanism following SCT. Additionally, we confirmed our previous results that patients with SIADH showed a higher overall survival and event-free survival rates. However, we first suggested that they had some neurological disorders and that neurological sequelae such as developmental delay and seizures would consequently occur.
Suzuki
Y
Y
Department of Pediatrics, Oji General Hospital, Tomakomai, Hokkaido, Japan. yoshisuzu_mail@yahoo.co.jp
Kobayashi
R
R
Iguchi
A
A
Sato
T
T
Kaneda
M
M
Kobayashi
K
K
Ariga
T
T
D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000378:metabolism; D005260:Female; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000209:etiology*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D015999:Multivariate Analysis; D009422:Nervous System Diseases / Q000209:etiology; D033581:Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods*; D016896:Treatment Outcome
D016207:Cytokines